Conference Correspondent

Conference Correspondent

Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.

Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.

This phase 2 study of elotuzumab, lenalidomide, and dexamethasone combination therapy in a high-risk population of patients with smoldering multiple myeloma showed promising efficacy and tolerability.

New treatment approaches are needed in multiple myeloma to extend relapse-free intervals and overall survival. In a phase 1/2 trial, the combination of pomalidomide, dexamethasone, and weekly carfilzomib showed impressive efficacy with acceptable tolerability.

In this analysis, Connect MM, a large observational disease registry, was used to characterize evolving treatment patterns and outcomes for patients with newly diagnosed multiple myeloma.

Recent study findings presented at the ASH 2016 Annual Meeting suggest that pomalidomide and low-dose dexamethasone can be used immediately following lenalidomide-based therapy to treat patients with relapsed/refractory multiple myeloma.

Treatment with ibrutinib in patients with chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma who had disease progression following allogeneic stem-cell transplantation resulted in a 77% overall response rate with a predicted 1-year overall survival of 92%.
In the prospective, open-label, multicenter, phase 2 CLL2-BIG trial, induction treatment with obinutuzumab and ibrutinib followed by maintenance therapy with continuous ibrutinib and obinutuzumab in a heterogeneous CLL population resulted in an overall response rate of 100% and an minimal residual disease–negativity rate of 47% in the peripheral blood, with no major toxicity.
In a multicenter, retrospective analysis of 683 patients with chronic lymphocytic leukemia (CLL), relative efficacy and optimal sequencing of ibrutinib (Ibr), idelalisib (Ide), and venetoclax (Ven) were evaluated. Using overall response rate and progression-free survival as clinical end points, Ibr appears superior to Ide in all settings as first choice kinase inhibitor (KI). In the setting of KI failure, an alternate KI or Ven therapy appears superior to chemoimmunotherapy, whereas an alternate KI appears particularly effective in the setting of intolerance to a prior KI. The use of Ven upon Ibr failure may be superior to the use of Ide. These data provide guidance for sequencing of novel agents.
Healthcare utilization of chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR). Patients aged ≥70 years receiving FCR experienced significantly more days of hospitalization, outpatient visits, and emergency department visits than patients of the same age treated with BR, suggesting BR as an effective, safe, and value-based treatment option for elderly CLL patients.
Page 3 of 7
Results 21 - 30 of 61
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME